MDCX.US Medicus Pharma Ltd. Common Stock

Healthcare Biotechnology USA Stocks
1.95 USD
Close of Nov 15, 2026
1.63 115.50
Market cap
USD 3.75M
P/E
-
P/B
11.97x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MDCX.US undervalued?

Graham number

The Graham number of Medicus Pharma Ltd. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Medicus Pharma Ltd. Common Stock fundamental analysis

No fundamental analysis for Medicus Pharma Ltd. Common Stock yet.

Medicus Pharma Ltd. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed …

Full company profile